Following on from information provided to NICE by the company in July 2016, the appraisal of Gastroenteropancreatic neuroendocrine tumours (somatostatin, non-progressive) - lutetium-177 DOTATAT [ID857] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
|
Status
|
Discontinued
|
|
Technology type
|
Medicine
|
|
Decision
|
Selected
|
| Process |
TA
|
| ID number |
857
|
Email enquiries
| External Assessment Group |
Liverpool Reviews and Implementation Group, University of Liverpool |
Stakeholders
| Companies sponsors |
Imaging Equipment (lutetium-177 DOTATATE) |
| Others |
Department of Health |
| |
NHS England |
| |
Welsh Government |
| Professional groups |
British Nuclear Medicine Society |
| |
Cancer Research UK |
| |
Royal College of Physicians |
| |
Royal College of Radiographers |
| |
UK and Ireland Neuroendocrine Tumour Society (UKI NETS) |
| Comparator companies |
Hospira UK - CAU not returned, not participating |
| |
Ipsen - CAU not returned, not participating |
| |
Novartis Pharmaceuticals UK - CAU not returned, not participating |
| |
Sun Pharmaceuticals UK - CAU not returned, not participating |
| General commentators |
All Wales Therapeutics and Toxicology Centre |
| |
British National Formulary |
| |
Department of Health, Social Services and Public Safety for Northern Ireland |
| |
Healthcare Improvement Scotland |
| |
Welsh Health Specialised Services Committee |
| Relevant research groups |
Institute of Cancer Research |